Director at Plus Therapeutics (PSTV) receives new equity awards
Rhea-AI Filing Summary
Plus Therapeutics director Kyle Guse reported receiving new equity compensation awards. He was granted stock options covering 3,686 shares of Common Stock at an exercise price of $5.76 per share, expiring on May 14, 2036. These options vest monthly over 12 months and will vest in full at the company’s 2027 Annual Stockholder Meeting, subject to continued service.
He was also granted 3,686 Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The RSUs vest in four equal quarterly installments, starting with one-quarter vesting on July 1, 2026, with the remainder vesting quarterly thereafter. The filing shows no open-market buys or sells, only grants classified as acquisitions.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Guse Kyle
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 3,686 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 3,686 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 3,686 shares (Direct);
Stock Option (Right to Buy) — 3,686 shares (Direct)
Footnotes (2)
- F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
- F2. The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.
Key Figures
Stock options granted: 3,686 options
Option exercise price: $5.76 per share
Option expiration: May 14, 2036
+3 more
6 metrics
Stock options granted
3,686 options
Grant dated May 14, 2026
Option exercise price
$5.76 per share
Stock Option (Right to Buy) grant
Option expiration
May 14, 2036
Expiration date for granted options
RSUs granted
3,686 RSUs
Grant dated May 14, 2026
RSU initial vesting date
July 1, 2026
First 1/4 of RSUs vest
Post-grant RSU holdings
3,686 RSUs
Total RSUs following transaction
Key Terms
Restricted Stock Unit, Stock Option (Right to Buy, exercise price, Annual Stockholder Meeting, +1 more
5 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "5.7600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Annual Stockholder Meeting regulatory
"options vest in full on the Issuer's 2027 Annual Stockholder Meeting..."
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
vest financial
"The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did Kyle Guse report for Plus Therapeutics (PSTV)?
Kyle Guse reported grants of stock options and Restricted Stock Units. He received options for 3,686 shares at a $5.76 exercise price and 3,686 RSUs, each representing a right to receive one share of Plus Therapeutics Common Stock, subject to vesting.
How do Kyle Guse’s new Plus Therapeutics (PSTV) stock options vest?
The options vest monthly over 12 months from the May 14, 2026 grant date. They are scheduled to vest in full at Plus Therapeutics’ 2027 Annual Stockholder Meeting, assuming Kyle Guse continues serving the company through each vesting date or that meeting.
What is the vesting schedule for Kyle Guse’s Plus Therapeutics (PSTV) RSUs?
The 3,686 RSUs vest ratably over four quarters. One-quarter vests on July 1, 2026, with the remaining three-quarters vesting in substantially equal quarterly installments thereafter, contingent on Kyle Guse’s continued service to Plus Therapeutics through each vesting date.
What does each Restricted Stock Unit represent for Plus Therapeutics (PSTV)?
Each Restricted Stock Unit represents a contingent right to receive one share of Plus Therapeutics Common Stock. Shares are delivered only as the RSUs vest over time, meaning Kyle Guse must satisfy the vesting conditions before receiving the underlying Common Stock.
When do Kyle Guse’s Plus Therapeutics (PSTV) stock options expire?
The stock options granted to Kyle Guse on May 14, 2026 carry an expiration date of May 14, 2036. He may exercise these options, once vested, at an exercise price of $5.76 per share any time before that expiration date, subject to plan terms.